Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Status: Closed to Accrual

Learn more:

• clinicaltrials.gov: #NCT03558087
• News release

Abstracts/Posters/Presentations:

• MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O’Neil, A D’souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU16-257. Presented as an oral abstract at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4503) See abstract. See related coverage at cancernetwork.com.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.